Immufact
Immufact Uses, Dosage, Side Effects, Food Interaction and all others data.
Immufact is under investigation in clinical trial NCT02614833 (IMP321 (Eftilagimod Alpha) as Adjunctive to a Standard Chemotherapy Paclitaxel Metastatic Breast Carcinoma).
| Trade Name | Immufact |
| Generic | Eftilagimod alfa |
| Eftilagimod alfa Other Names | Eftilagimod alfa, Immufact |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Innovators Monograph
You find simplified version here Immufact
